Last reviewed · How we verify
aspirin and [NSAID]
This combination product pairs aspirin with an NSAID to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity through a fixed-dose formulation.
This combination product pairs aspirin with an NSAID to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity through a fixed-dose formulation. Used for Acute pain management, Cardiovascular protection (aspirin component).
At a glance
| Generic name | aspirin and [NSAID] |
|---|---|
| Sponsor | POZEN |
| Drug class | NSAID combination |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to block prostaglandin synthesis, providing antiplatelet and anti-inflammatory effects. The addition of an NSAID (specific agent not specified in the designation) provides complementary COX inhibition for enhanced analgesia and anti-inflammation. POZEN's formulation approach aims to optimize the therapeutic benefit-risk profile, though combining two NSAIDs/aspirin typically requires careful GI protection strategies.
Approved indications
- Acute pain management
- Cardiovascular protection (aspirin component)
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Abdominal pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin and [NSAID] CI brief — competitive landscape report
- aspirin and [NSAID] updates RSS · CI watch RSS
- POZEN portfolio CI